Rockwell Medical(NASDAQ) RMTI

Rockwell Medical makes products for people with kidney failure who need dialysis. Its solutions help remove toxins and replace nutrients during treatment. The company’s products are used by clinics and hospitals to support patient care.

Dialysis Essentials: What Rockwell Medical Sells

• Hemodialysis Concentrates: Liquid and dry acid and bicarbonate solutions for dialysis, making up 100% of 2025 revenue; used to clean blood and balance body chemistry in patients with kidney failure.
• Mixing Systems: Equipment for clinics to prepare dialysis solutions on-site, supporting operational efficiency for dialysis providers.
• Ancillary Supplies: Blood tubing, needles, dialyzers, and cleaning agents, all supporting the dialysis process for clinics and hospitals.
• Iron Therapy Products: Triferic Dialysate and Triferic AVNU, which help maintain iron levels in dialysis patients; these are used to avoid iron deficiency during treatment.
• Therapeutic Candidates: Products in development for heart failure and home infusion therapy, aiming to expand treatment options for patients outside hospitals.

Growth Moves: Rockwell’s Expansion Playbook

• Launched single-use bicarbonate cartridge in 2025, expanding product line for dialysis clinics.
• Signed multi-year supply agreement with Innovative Renal Care in 2025, strengthening customer base.
• Extended and amended contract with DaVita through 2026, including price increases.
• Added 30 new customers in the western U.S. in 2025, increasing clinic footprint.
• Closed South Carolina facility in 2025 to streamline operations and reduce costs.

What Makes Rockwell Medical Stand Out

Rockwell Medical supplies all five leading U.S. dialysis providers and distributes to over 12,000 facilities. Its Texas plant holds ISO 13485:2016 certification, reflecting a focus on quality. The company’s own delivery fleet and third-party carriers support broad U.S. and international reach.

Five Things You Need to Know

• Net sales were $69.3 million in 2025, down 31.8% from 2024.
• Gross profit was $11.7 million in 2025, a 16.9% margin.
• International sales made up approximately 12% of total sales in 2025.
• Operating loss was $4.7 million in 2025, compared to income in 2024.
• Cash and investments totaled $25 million at year-end 2025.

Bottom Line

Rockwell Medical has adapted to shifting customer demand and cost pressures by streamlining operations and expanding its product range. The company remains focused on serving dialysis providers with essential products and services.